• Ajay Patel, Tuo Dong, Shaheryar Ansari, Aaron Cohen-Gadol, Gordon A Watson, Fabio Ynoe de Moraes, Masaki Nakamura, Judith Murovic, Steven D Chang, Mustafa Aziz Hatiboglu, Caroline Chung, James C Miller, and Tim Lautenschlaeger.
• Indiana University School of Medicine, Indianapolis, Indiana, USA.
• World Neurosurg. 2018 Nov 1; 119: e757-e764.

BackgroundAlthough stereotactic radiosurgery (SRS) is an effective modality in the treatment of brainstem metastases (BSM), radiation-induced toxicity remains a critical concern. To better understand how severe or life-threatening toxicity is affected by the location of lesions treated in the brainstem, a review of all available studies reporting SRS treatment for BSM was performed.MethodsTwenty-nine retrospective studies investigating SRS for BSM were reviewed.ResultsThe rates of grade 3 or greater toxicity, based on the Common Terminology Criteria for Adverse Events, varied from 0 to 9.5% (mean 3.4 ± 2.9%). Overall, the median time to toxicity after SRS was 3 months, with 90% of toxicities occurring before 9 months. A total of 1243 cases had toxicity and location data available. Toxicity rates for lesions located in the medulla were 0.8% (1/131), compared with midbrain and pons, respectively, 2.8% (8/288) and 3.0% (24/811).ConclusionsCurrent data suggest that brainstem substructure location does not predict for toxicity and lesion volume within this cohort with median tumor volumes 0.04-2.8 cc does not predict for toxicity.Copyright © 2018 Elsevier Inc. All rights reserved.

18 keywords...

hide…